ClinicalTrials.gg
CompletedNCT03792672Updated Mar 19, 2021Results posted

A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)

A Phase 1 interventional study of TAK-653 and Placebo in Healthy Volunteers, sponsored by Neurocrine Biosciences. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Neurocrine Biosciences · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of this study is to determine whether TAK-653, in comparison to placebo, increases CNS excitability, assessed with TMS-evoked motor-evoked potential (MEP) in healthy participants.

Read the detailed description

The drug being tested in this study is called TAK-653. This study is designed to evaluate the central pharmacodynamic activity of TAK-653 using TMS. The study will enroll approximately 24 participants to yield 22 participants that complete treatment periods 1, 2, and 3. Participants will be randomly assigned to 1 of the 6 sequences to receive TAK-653 0.5 mg low dose or TAK-653 6 mg high dose or Placebo in double-blind treatment periods 1, 2, and 3, followed by Ketamine 0.5 mg/kg in open-label Treatment period 4.

All participants will receive one dose of TAK-653 (0.5 or 6 mg), or Placebo or Ketamine on Day 1 of each treatment period.

This single center trial will be conducted in the Netherlands. The overall time to participate in this study is 15 weeks. Participants will make 5 visits to the clinic. A washout period of minimum 10 days will be maintained between the doses in treatment periods 1 to 3. Follow-up phone call will be made on Day 14.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be judged to be in good health by the investigator, based on clinical evaluations including laboratory safety tests, medical history, physical examination, 12-lead (ECG), and vital sign measurements performed at the screening visit and before the first dose of study drug.
  2. Must be male or female (of nonchildbearing potential) aged 18 to 55 years, inclusive, at the screening visit.
  3. Must have a (BMI) greater than or equal to (>=) 18.5 and less than or equal to (\<=) 30.0 kilogram per square meter (kg/m\^2) at the screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Has a positive alcohol or drug screen.
  2. Had major surgery or donated or lost 1 unit of blood (approximately 500 milliliter [mL]) within 4 weeks before the screening visit.
  3. Has a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer [354 mL/12 ounce (oz)], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz] per day).
  4. Who regularly smoke more than 5 cigarettes daily or equivalent and unable or unwilling not to smoke during the in-house period.
  5. Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
  6. Has a previous or current psychiatric disorder according to , Fifth Edition, (DSM-5) including substance use disorder.
  7. Has a history of intracranial mass lesion, hydrocephalus and/or head injury or trauma.
  8. Has metal objects in brain or skull.
  9. Has a cochlear implant or deep brain stimulation device.
  10. Has a history of epilepsy, seizures, or convulsions.
  11. Has a family history of epilepsy, seizures, or convulsions.
  12. Has abnormal sleeping patterns (example, working night shifts)
  13. Has an rMT of more than 75% of the maximum stimulator output, measured using TMS-electromyogram (EMG) during screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg

    TAK-653 6 milligram (mg) high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 milligram per kilogram (mg/kg), intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.

    Drug: TAK-653 · Drug: Placebo · Drug: Ketamine

  • Experimental
    TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg

    TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.

    Drug: TAK-653 · Drug: Placebo · Drug: Ketamine

  • Experimental
    TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg

    TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.

    Drug: TAK-653 · Drug: Placebo · Drug: Ketamine

  • Experimental
    TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg

    TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.

    Drug: TAK-653 · Drug: Placebo · Drug: Ketamine

  • Experimental
    Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg

    TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.

    Drug: TAK-653 · Drug: Placebo · Drug: Ketamine

  • Experimental
    Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg

    TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.

    Drug: TAK-653 · Drug: Placebo · Drug: Ketamine

Interventions

  • TAK-653 tablets.

  • DrugPlacebo

    TAK-653 placebo-matching tablets.

  • Ketamine intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Peak-to-Peak Amplitude of Motor-evoked Potential (MEP) Obtained With Single-pulse Transcranial Magnetic Stimulation (TMS) for TAK-653 at 2.5 Hours Post TAK-653 Dose

    TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Single-pulse TMS was used to determine peak-to-peak amplitude of MEP at a stimulation intensity of 120 percent (%) of baseline resting motor threshold (rMT). rMT was defined as the minimum stimulus intensity to evoke an MEP. Change in peak-to peak amplitude of MEP was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 versus (vs.) matched oral placebo.

    Time frame: Baseline, 2.5 hours post TAK-653 dose

  2. Change From Baseline in Resting Motor Threshold (rMT) Obtained With Single-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose

    The rMT was defined as the minimum stimulus intensity to evoke an MEP. Single-pulse TMS was used to determine rMT. A lower rMT value indicated greater neuronal excitability. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in rMT was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.

    Time frame: Baseline, 2.5 hours post TAK-653 dose

Secondary outcomes

  1. Change From Baseline in Magnitude of Long Intracortical Inhibition (LICI) Obtained With Paired-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose

    LICI was TMS stimulation paradigm that capture modulation of cortical excitation-inhibition balance with pairs of TMS pulses at stimulation intensity conditioning pulse and test pulse of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in LICI was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.

    Time frame: Baseline, 2.5 hours post TAK-653 dose

  2. Change From Baseline in Magnitude of Short Intracortical Inhibition (SICI) Obtained With Paired-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose

    SICI was TMS stimulation paradigm that capture modulation of cortical excitation-inhibition balance with pairs of TMS pulses at stimulation intensity conditioning pulse 80% of baseline rMT and test pulse of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in SICI was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.

    Time frame: Baseline, 2.5 hours post TAK-653 dose

  3. Change From Baseline in rMT Obtained With Single-pulse TMS to Assess the Effect of Ketamine at 2.5 Hours and 24 Hours Post-dose of Ketamine

    The rMT was defined as the minimum stimulus intensity to evoke an MEP. Single-pulse TMS was used to determine rMT. A lower rMT value indicated greater neuronal excitability. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in rMT was be assessed by TMS after treatment with 0.5 mg/kg Ketamine.

    Time frame: Baseline, 2.5 hours post ketamine dose, and 24 hours post ketamine dose

  4. Change From Baseline in in Peak-to-Peak Amplitude of MEP Obtained With Single-pulse TMS to Assess the Effect of Ketamine at 2.5 Hours and 24 Hours Post Dose of Ketamine

    TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Single-pulse TMS was used to determine peak-to-peak amplitude of MEP at a stimulation intensity of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. Change in peak-to peak amplitude of MEP was be assessed by TMS after treatment 0.5 mg/kg Ketamine.

    Time frame: Baseline, 2.5 hours post ketamine dose, and 24 hours post ketamine dose

07

Results

Posted Jul 2, 2020

Participant flow

Participants took part in the study at 1 investigative site in Netherlands from 11 February 2019 to 18 June 2019.

Treatment Period 1 (1 Day)
Participant flow — Treatment Period 1 (1 Day)
MilestonePlacebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kgPlacebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kgTAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg
Started444444
Completed444444
Not completed000000
Washout Period 1 (10 Days)
Participant flow — Washout Period 1 (10 Days)
MilestonePlacebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kgPlacebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kgTAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg
Started444444
Completed444444
Not completed000000
Treatment Period 2 (1 Day)
Participant flow — Treatment Period 2 (1 Day)
MilestonePlacebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kgPlacebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kgTAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg
Started444444
Completed444444
Not completed000000
Washout Period 2 (10 Days)
Participant flow — Washout Period 2 (10 Days)
MilestonePlacebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kgPlacebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kgTAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg
Started444444
Completed444444
Not completed000000
Treatment Period 3 (1 Day)
Participant flow — Treatment Period 3 (1 Day)
MilestonePlacebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kgPlacebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kgTAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg
Started444444
Completed444444
Not completed000000
Washout Period 3 (10 Days)
Participant flow — Washout Period 3 (10 Days)
MilestonePlacebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kgPlacebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kgTAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg
Started444444
Completed343244
Not completed101200
Withdrew: Withdrawal by subject100200
Withdrew: Physician decision001000
Treatment Period 4 (2 Days)
Participant flow — Treatment Period 4 (2 Days)
MilestonePlacebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kgPlacebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kgTAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kgTAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kgTAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg
Started343244
Completed243244
Not completed100000
Withdrew: Other100000

Outcome measures

PrimaryChange From Baseline in Peak-to-Peak Amplitude of Motor-evoked Potential (MEP) Obtained With Single-pulse Transcranial Magnetic Stimulation (TMS) for TAK-653 at 2.5 Hours Post TAK-653 Dose

TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Single-pulse TMS was used to determine peak-to-peak amplitude of MEP at a stimulation intensity of 120 percent (%) of baseline resting motor threshold (rMT). rMT was defined as the minimum stimulus intensity to evoke an MEP. Change in peak-to peak amplitude of MEP was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 versus (vs.) matched oral placebo.

Time frame:
Baseline, 2.5 hours post TAK-653 dose
Reported as:
Mean · microvolt (mcV)
Change From Baseline in Peak-to-Peak Amplitude of Motor-evoked Potential (MEP) Obtained With Single-pulse Transcranial Magnetic Stimulation (TMS) for TAK-653 at 2.5 Hours Post TAK-653 Dose
microvolt (mcV)PlaceboTAK-653 0.5 mgTAK-653 6 mg
Baseline898.828 ± 693.1535841.068 ± 591.13671004.127 ± 574.5982
Change at 2.5 Hours Post TAK-653 Dose-139.117 ± 829.590117.265 ± 466.2556139.932 ± 813.9705
Statistical analysis
  • Placebo vs TAK-653 0.5 mg · Mixed Models Analysis · p = 0.4278 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Least square mean (lsm) difference: 115 · 90% CI -128 to 359
  • Placebo vs TAK-653 6 mg · Mixed Models Analysis · p = 0.0269 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: 338 · 90% CI 90.5 to 585
PrimaryChange From Baseline in Resting Motor Threshold (rMT) Obtained With Single-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose

The rMT was defined as the minimum stimulus intensity to evoke an MEP. Single-pulse TMS was used to determine rMT. A lower rMT value indicated greater neuronal excitability. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in rMT was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.

Time frame:
Baseline, 2.5 hours post TAK-653 dose
Reported as:
Mean · percentage of maximum stimulator output
Change From Baseline in Resting Motor Threshold (rMT) Obtained With Single-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose
percentage of maximum stimulator outputPlaceboTAK-653 0.5 mgTAK-653 6 mg
Baseline55.3 ± 7.4655.9 ± 8.9955.3 ± 8.93
Change at 2.5 hours post TAK-653 Dose-0.1 ± 2.74-0.5 ± 1.74-0.3 ± 1.95
Statistical analysis
  • Placebo vs TAK-653 0.5 mg · Mixed Models Analysis · p = 0.5089 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: -0.388 · 90% CI -1.37 to 0.595
  • Placebo vs TAK-653 6 mg · Mixed Models Analysis · p = 0.7208 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: -0.209 · 90% CI -1.19 to 0.773
SecondaryChange From Baseline in Magnitude of Long Intracortical Inhibition (LICI) Obtained With Paired-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose

LICI was TMS stimulation paradigm that capture modulation of cortical excitation-inhibition balance with pairs of TMS pulses at stimulation intensity conditioning pulse and test pulse of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in LICI was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.

Time frame:
Baseline, 2.5 hours post TAK-653 dose
Reported as:
Mean · percent inhibition
Change From Baseline in Magnitude of Long Intracortical Inhibition (LICI) Obtained With Paired-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose
percent inhibitionPlaceboTAK-653 0.5 mgTAK-653 6 mg
Baseline: LICI 50 ms75.113 ± 97.286596.515 ± 113.272896.568 ± 111.1657
Change at 2.5 Hours Post TAK-653 Dose: LICI 50 ms0.675 ± 54.572518.319 ± 81.437819.395 ± 110.0870
Baseline: LICI 100 ms16.167 ± 27.097610.430 ± 14.128946.808 ± 149.9806
Change at 2.5 Hours Post TAK-653 Dose: LICI 100 ms0.147 ± 29.15675.905 ± 18.8939-28.644 ± 142.5618
Baseline: LICI 200 ms48.149 ± 33.181548.934 ± 48.607349.773 ± 37.7173
Change at 2.5 Hours Post TAK-653 Dose: LICI 200 ms2.882 ± 21.24599.902 ± 42.576111.540 ± 30.1594
Baseline: LICI 300 ms59.463 ± 31.159656.115 ± 36.845254.572 ± 30.5543
Change at 2.5 Hours Post TAK-653 Dose: LICI 300 ms-9.996 ± 27.71518.618 ± 36.04531.638 ± 32.6843
Statistical analysis
  • Placebo vs TAK-653 0.5 mg · Mixed Models Analysis · p = 0.4174 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: 14.0 · 90% CI -14.8 to 42.8
  • Placebo vs TAK-653 6 mg · Mixed Models Analysis · p = 0.3832 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: 15.1 · 90% CI -25.3 to 31.5
  • Placebo vs TAK-653 0.5 mg · Mixed Models Analysis · p = 0.9368 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: -0.326 · 90% CI -7.23 to 6.58
  • Placebo vs TAK-653 6 mg · Mixed Models Analysis · p = 0.3790 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: 3.71 · 90% CI -3.32 to 10.7
  • Placebo vs TAK-653 0.5 mg · Mixed Models Analysis · p = 0.2580 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: 7.36 · 90% CI -3.44 to 18.2
  • Placebo vs TAK-653 6 mg · Mixed Models Analysis · p = 0.1524 · Lsm difference: 9.36 · 90% CI -1.45 to 20.2
  • Placebo vs TAK-653 0.5 mg · Mixed Models Analysis · p = 0.0220 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: 17.2 · 90% CI 5.06 to 29.4
  • Placebo vs TAK-653 6 mg · Mixed Models Analysis · p = 0.1927 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: 9.58 · 90% CI -2.59 to 21.8
SecondaryChange From Baseline in Magnitude of Short Intracortical Inhibition (SICI) Obtained With Paired-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose

SICI was TMS stimulation paradigm that capture modulation of cortical excitation-inhibition balance with pairs of TMS pulses at stimulation intensity conditioning pulse 80% of baseline rMT and test pulse of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in SICI was be assessed by TMS after treatment with 0.5 mg or 6 mg of TAK-653 vs. matched oral placebo.

Time frame:
Baseline, 2.5 hours post TAK-653 dose
Reported as:
Mean · percent inhibition
Change From Baseline in Magnitude of Short Intracortical Inhibition (SICI) Obtained With Paired-pulse TMS for TAK-653 at 2.5 Hours Post TAK-653 Dose
percent inhibitionPlaceboTAK-653 0.5 mgTAK-653 6 mg
Baseline: SICI 2 ms43.095 ± 30.701139.159 ± 39.253647.951 ± 42.1139
Change at 2.5 Hours Post TAK-653 Dose: SICI 2 ms5.052 ± 47.56761.772 ± 35.9158-14.580 ± 37.7311
Baseline: SICI 5 ms70.640 ± 49.869959.672 ± 37.741972.722 ± 62.0484
Change at 2.5 Hours Post TAK-653 Dose: SICI 5 ms14.303 ± 81.61114.274 ± 30.8966-7.247 ± 52.9205
Statistical analysis
  • Placebo vs TAK-653 0.5 mg · Mixed Models Analysis · p = 0.5590 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: -5.65 · 90% CI -21.8 to 10.5
  • Placebo vs TAK-653 6 mg · Mixed Models Analysis · p = 0.1049 · Lsm difference: -16.1 · 90% CI -32.5 to 0.242
  • Placebo vs TAK-653 0.5 mg · Mixed Models Analysis · p = 0.2238 (Based on mixed model analysis, with treatment, period, sequence, treatment-by-period interaction as fixed factors, participant within sequence as a random factor, baseline as a covariate.) · Lsm difference: -16.7 · 90% CI -39.4 to 6.06
  • Placebo vs TAK-653 6 mg · Mixed Models Analysis · p = 0.1847 · Lsm difference: -18.3 · 90% CI -41.3 to 4.56
SecondaryChange From Baseline in rMT Obtained With Single-pulse TMS to Assess the Effect of Ketamine at 2.5 Hours and 24 Hours Post-dose of Ketamine

The rMT was defined as the minimum stimulus intensity to evoke an MEP. Single-pulse TMS was used to determine rMT. A lower rMT value indicated greater neuronal excitability. TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Change in rMT was be assessed by TMS after treatment with 0.5 mg/kg Ketamine.

Time frame:
Baseline, 2.5 hours post ketamine dose, and 24 hours post ketamine dose
Reported as:
Mean · percentage of maximum stimulator output
Change From Baseline in rMT Obtained With Single-pulse TMS to Assess the Effect of Ketamine at 2.5 Hours and 24 Hours Post-dose of Ketamine
percentage of maximum stimulator outputKetamine 0.5 mg/kg
Baseline54.4 ± 9.28
Change at 2.5 hours Ketamine Post Dose0.7 ± 4.18
Change at 24 hours Ketamine Post Dose0.8 ± 3.10
SecondaryChange From Baseline in in Peak-to-Peak Amplitude of MEP Obtained With Single-pulse TMS to Assess the Effect of Ketamine at 2.5 Hours and 24 Hours Post Dose of Ketamine

TMS was a neurophysiologic test for assessing upper motor neuron function. TMS was a noninvasive neuro stimulation method involving the application of brief magnetic pulses to the skull, based on the principles of electromagnetic induction, create an orthogonal electric current that can be sufficient to depolarize neurons and activate neuronal circuits. Single-pulse TMS was used to determine peak-to-peak amplitude of MEP at a stimulation intensity of 120% of baseline rMT. rMT was defined as the minimum stimulus intensity to evoke an MEP. Change in peak-to peak amplitude of MEP was be assessed by TMS after treatment 0.5 mg/kg Ketamine.

Time frame:
Baseline, 2.5 hours post ketamine dose, and 24 hours post ketamine dose
Reported as:
Mean · mcV
Change From Baseline in in Peak-to-Peak Amplitude of MEP Obtained With Single-pulse TMS to Assess the Effect of Ketamine at 2.5 Hours and 24 Hours Post Dose of Ketamine
mcVKetamine 0.5 mg/kg
Baseline1150.618 ± 1047.3920
Change at 2.5 hours Ketamine Post Dose-193.897 ± 897.0245
Change at 24 hours Ketamine Post Dose-295.041 ± 944.4889

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug until 14 days after last dose in Treatment Period 4 (up to Day 48). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/24 (0%)0/24 (0%)7/24 (29.2%)
TAK-653 0.5 mg0/24 (0%)0/24 (0%)9/24 (37.5%)
TAK-653 6 mg0/24 (0%)0/24 (0%)12/24 (50%)
Ketamine 0.5 mg/kg0/20 (0%)0/20 (0%)20/20 (100%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlaceboTAK-653 0.5 mgTAK-653 6 mgKetamine 0.5 mg/kg
DissociationPsychiatric disorders0/240/240/2415/20
DizzinessNervous system disorders1/240/241/248/20
NauseaGastrointestinal disorders1/240/241/245/20
HeadacheNervous system disorders2/241/244/243/20
SomnolenceNervous system disorders2/243/243/243/20
NasopharyngitisInfections and infestations0/243/241/240/20
Dry MouthGastrointestinal disorders0/240/240/242/20
Feeling ColdGeneral disorders0/240/240/242/20
Feeling DrunkGeneral disorders0/240/240/242/20
Vision BlurredEye disorders0/240/240/242/20

Baseline characteristics

The safety analysis set included all participants who were randomized and received at least 1 dose of study drug. Baseline characteristics data has been presented for overall participants analyzed.

Age, Continuous
Age, Continuous(years)All Participants
Mean27.9 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female1
Male23
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino24
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White22
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Participants
Netherlands24
Weight
Weight(kilogram (Kg))All Participants
Mean79.12 ± 10.81
Height
Height(centimeter (cm))All Participants
Mean181.98 ± 9.88
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))All Participants
Mean23.93 ± 2.85
08

Study locations

1 site
  • CHDR
    Leiden, Netherlands
09

References and documents

Publications

  • Dijkstra F, O'Donnell P, Klaassen E, Buhl D, Asgharnejad M, Rosen L, Zuiker R, van Gerven J, Jacobs G. Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers. Transl Psychiatry. 2022 Sep 24;12(1):408. doi: 10.1038/s41398-022-02148-w. PubMed 36153330 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in May 2019, 3 months.

Results were first posted in Jul 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2019
First posted
Jan 3, 2019
StartActual
Feb 11, 2019
Primary completionActual
May 15, 2019
CompletionActual
Jun 18, 2019
Results first posted
Jul 2, 2020
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03792672
Collaborators
Takeda
Responsible party
Sponsor
First posted
Jan 3, 2019
Start date
Feb 11, 2019
Primary completion
May 15, 2019
Completion
Jun 18, 2019
Results posted
Jul 2, 2020
Last update
Mar 19, 2021

Study contacts

Medical Director
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osavampator

Start the discussion